Impairment of homeostasis in lysosomal storage disorders

IUBMB Life

Volumn 66, Issue 7, 2014, Pages 472-477

  Segatori, Laura ^a,b  

^a Rice University   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

chaperones; genetics; human molecular disease; neurodegenerative disorders; protein folding; protein function

Indexed keywords

CALCIUM ION; CHAPERONE; LYSOSOMAL PROTEINS; PROTEIN;

AUTOPHAGY; BIOGENESIS; CALCIUM SIGNALING; ENDOSOME; EXOCYTOSIS; HOMEOSTASIS; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; METABOLIC STRESS; NONHUMAN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; REVIEW; ANIMAL; LYSOSOMAL STORAGE DISEASES; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; PROTEIN PROCESSING; SECRETORY PATHWAY;

ANIMALS; AUTOPHAGY; ENDOSOMES; HOMEOSTASIS; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; SECRETORY PATHWAY; STRESS, PHYSIOLOGICAL;

EID: 84906342558     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1288     Document Type: Review

References (66)

1. de Duve, C., Pressman, B. C., Gianetto, R., Wattiaux, R., and, Appelmans, F., (1955) Tissue fractionation studies. VI. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J. 60, 604-617.
2. Doherty, G. J., and, McMahon, H. T., (2009) Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 857-902.
3. Ravikumar, B., Futter, M., Jahreiss, L., Korolchuk, V. I., Lichtenberg, M., et al. (2009) Mammalian macroautophagy at a glance. J. Cell Sci. 122, 1707-1711.
4. Fuller, M., Meikle, P. J., and, Hopwood, J. J., (2006) Epidemiology of Lysosomal Storage Diseases: An Overview. Chapter 2, Oxford PharmaGenesis, Oxford.
5. Callahan, J. W., (1999) Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal β-galactosidase and the non-lysosomal β-galactosidase-like protein. Biochim. Biophys. Acta Mol. Cell Res. 1455, 85-103.
6. Wang, F., Song, W. S., Brancati, G., and, Segatori, L., (2011) Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J. Biol. Chem. 286, 43454-43464.
7. Wei, H., Kim, S. J., Zhang, Z., Tsai, P. C., Wisniewski, K. E., et al. (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet. 17, 469-477.
8. Lieberman, A. P., Puertollano, R., Raben, N., Slaugenhaupt, S., Walkley, S. U., et al. (2012) Autophagy in lysosomal storage disorders. Autophagy 8, 719-730.
9. Kiselyov, K., and, Muallem, S., (2008) Mitochondrial Ca(2+) homeostasis in lysosomal storage diseases. Cell Calcium 44, 103-111.
10. Meikle, P. J., Fietz, M. J., and, Hopwood, J. J., (2004) Diagnosis of lysosomal storage disorders: current techniques and future directions. Expert Rev. Mol. Diagn. 4, 677-691.
11. Vitner, E. B., Platt, F. M., and, Futerman, A. H., (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 285, 20423-20427.
12. Beutler, E., (2006) Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr. 95, 103-109.
13. Grace, M. E., Newman, K. M., Scheinker, V., Bergfussman, A., and, Grabowski, G. A., (1994) Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression. J. Biol. Chem. 269, 2283-2291.
14. Schmitz, M., Alfalah, M., Aerts, J. M. F. G., Naim, H. Y., and, Zimmer, K. P., (2005) Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease. Int. J. Biochem. Cell Biol. 37, 2310-2320.
15. Lu, J., Chiang, J., Iyer, R. R., Thompson, E., Kaneski, C. R., et al. (2010) Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc. Natl. Acad. Sci. USA 107, 21665-21670.
16. Sawkar, A. R., Cheng, W. C., Beutler, E., Wong, C. H., Balch, W. E., et al. (2002) Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA 99, 15428-15433.
17. Mu, T. W., Ong, D. S. T., Wang, Y. J., Balch, W. E., Yates, J. R., et al. (2008) Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134, 769-781.
18. Lu, J., Yang, C. Z., Chen, M., Ye, D. Y., Lonser, R. R., et al. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. USA 108, 21200-21205.
19. 2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts. ACS Chem. Biol. 6, 158-168.
20. 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. Chem. Biol. 18, 766-776.
21. Wang, F., and, Segatori, L., (2013) Remodeling the proteostasis network to rescue glucocerebrosidase variants by inhibiting ER-associated degradation and enhancing ER folding. PLoS One 8, e61418.
22. Futerman, A. H., (2010) Calcium homeostasis in lysosomal storage diseases. Int. J. Clin. Pharmacol. Ther. 48, S6-S7.
23. Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., et al. (2009) A gene network regulating lysosomal biogenesis and function. Science 325, 473-477.
24. Palmieri, M., Impey, S., Kang, H. J., di Ronza, A., Pelz, C., et al. (2011) Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 20, 3852-3866.
25. Medina, D. L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., et al. (2011) Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev. Cell 21, 421-430.
26. Settembre, C., Di Malta, C., Polito, V. A., Garcia-Arencibia, M., Vetrini, F., et al. (2011) TFEB links autophagy to lysosomal biogenesis. Science 332, 1429-1433.
27. Song, W. S., Wang, F., Savini, M., Ake, A., Di Ronza, A., et al. (2013) TFEB regulates lysosomal proteostasis. Hum. Mol. Genet. 22, 1994-2009.
28. Jahreiss, L., Menzies, F. M., and, Rubinsztein, D. C., (2008) The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic 9, 574-587.
29. Walkley, S. U., and, Vanier, M. T., (2009) Secondary lipid accumulation in lysosomal disease. Biochim. Biophys. Acta Mol. Cell Res. 1793, 726-736.
30. Prinetti, A., Prioni, S., Chiricozzi, E., Schuchman, E. H., Chigorno, V., et al. (2011) Secondary alterations of sphingolipid metabolism in lysosomal storage diseases. Neurochem. Res. 36, 1654-1668.
31. Lamanna, W. C., Lawrence, R., Sarrazin, S., and, Esko, J. D., (2011) Secondary storage of dermatan sulfate in Sanfilippo disease. J. Biol. Chem. 286, 6955-6962.
32. Wang, C. W., and, Klionsky, D. J., (2003) The molecular mechanism of autophagy. Mol. Med. 9, 65-76.
33. Ballabio, A., and, Gieselmann, V., (2009) Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta Mol. Cell Res. 1793, 684-696.
34. Ballabio, A., (2009) Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders. Int. J. Clin. Pharmacol. Ther. 47, S34-S38.
35. Koike, M., Shibata, M., Waguri, S., Yoshimura, K., Tanida, I., et al. (2005) Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am. J. Pathol. 167, 1713-1728.
36. Cao, Y., Espinola, J. A., Fossale, E., Massey, A. C., Cuervo, A. M., et al. (2006) Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 281, 20483-20493.
37. Settembre, C., Fraldi, A., Jahreiss, L., Spampanato, C., Venturi, C., et al. (2008) A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet. 17, 119-129.
38. Takikita, S., Myerowitz, R., Schreiner, C., Baum, R., Raben, N., et al. (2009) The values and limits of an in vitro model of Pompe disease. The best laid schemes o' mice an' men.... Autophagy 5, 729-731.
39. Cuervo, A. M., and, Dice, J. F., (2000) Regulation of Lamp2a levels in the lysosomal membrane. Traffic 1, 570-583.
40. Fidzianska, A., Walczak, E., and, Walski, M., (2007) Abnormal chaperone-mediated autophagy (CMA) in cardiomyocytes of a boy with Danon disease. Folia Neuropathol. 45, 133-139.
41. Venugopal, B., Mesires, N. T., Kennedy, J. C., Curcio-Morelli, C., Laplante, J. M., et al. (2009) Chaperone-mediated autophagy is defective in mucolipidosis type IV. J. Cell. Physiol. 219, 344-353.
42. Suzuki, K., Iseki, E., Togo, T., Yamaguchi, A., Katsuse, O., et al. (2007) Neuronal and glial accumulation of α- and β-synucleins in human lipidoses. Acta Neuropathol. 114, 481-489.
43. Ravikumar, B., Duden, R., and, Rubinsztein, D. C., (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107-1117.
44. Wong, E., and, Cuervo, A. M.,., (2010) Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805-811.
45. Lee, J. H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., et al. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, U1146-U1191.
46. Sardiello, M., and, Ballabio, A., (2009) Lysosomal enhancement: a CLEAR answer to cellular degradative needs. Cell Cycle 8, 4021-4022.
47. Spampanato, C., Feeney, E., Li, L. S., Cardone, M., Lim, J. A., et al. (2013) Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol. Med. 5, 691-706.
48. Kitatani, K., Idkowiak-Baldys, J., and, Hannun, Y. A., (2008) The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell. Signal. 20, 1010-1018.
49. Brady, R. O., (2010) Benefits from unearthing "a biochemical Rosetta Stone." J. Biol. Chem. 285, 41216-41221.
50. Rohrbach, M., and, Clarke, J. T. R., (2007) Treatment of lysosomal storage disorders-progress with enzyme replacement therapy. Drugs 67, 2697-2716.
51. Desnick, R. J., and, Schuchman, E. H., (2012) Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307-335.
52. Beutler, E., (2004) Enzyme replacement in Gaucher disease. PLoS Med. 1, 118-121.
53. Altarescu, G., Hill, S., Wiggs, E., Jeffries, N., Kreps, C., et al. (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr. 138, 539-547.
54. Lund, T. C., (2013) Hematopoietic stem cell transplant for lysosomal storage diseases. Pediatr. Endocrinol. Rev. 11, 91-98.
55. Prasad, V. K., and, Kurtzberg, J., (2010) Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br. J. Haematol. 148, 356-372.
56. Schueler, U. H., Kolter, T., Kaneski, C. R., Zirzow, G. C., Sandhoff, K., et al. (2004) Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J. Inherit. Metab. Dis. 27, 649-658.
57. Seregin, S. S., and, Amalfitano, A., (2011) Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Curr. Pharm. Des. 17, 2558-2574.
58. Lachmann, R. H., (2006) Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders. Drugs Today (Barc) 42, 29-38.
59. Patterson, M. C., Vecchio, D., Prady, H., Abel, L., and, Wraith, J. E., (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 6, 765-772.
60. Cox, T. M., (2010) Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr. Opin. Investig. Drugs 11, 1169-1181.
61. Kamath, R. S., Lukina, E., Watman, N., Dragosky, M., Pastores, G. M., et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol., 2014 May 10.
62. Davidson, C. D., Ali, N. F., Micsenyi, M. C., Stephney, G., Renault, S., et al. (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4, e6951.
63. Song, W., Wang, F., Lotfi, P., Sardiello, M., and, Segatori, L., (2014) 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J. Biol. Chem. 289, 10211-10222.
64. Strauss, K., Goebel, C., Runz, H., Mobius, W., Weiss, S., et al. (2010) Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease. J. Biol. Chem. 285, 26279-26288.
65. Kirkegaard, T., Roth, A. G., Petersen, N. H., Mahalka, A. K., Olsen, O. D., et al. (2010) Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 463, 549-553.
66. Mu, T. W., Fowler, D. M., and, Kelly, J. W., (2008) Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 6, 253-265.